uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
Key claim: A uPAR-targeting T cell engager clears senescent cells in mice and non-human primates, with serum aminotransferase activity usable as a safety monitor.
Abstract
Aging Cell, Volume 25, Issue 10, October 2026.
Why this matters
Senolytic cell therapies have been almost entirely mouse-stage; moving a uPAR-directed T-cell engager into non-human primates with a cheap, routine liver-enzyme readout for dose-finding is the kind of translational step that lets a preclinical modality start being discussed by longevity clinics and biotech watchers as ‘near-human.’ It also reinforces uPAR as the current consensus senescent-cell antigen across both BiTE and CAR-T programs. The evidence remains preclinical — the trend-vs-evidence gap is that primate data will be read in popular channels as near-clinical validation when no human efficacy or safety data exist yet.